--Welcome and Program Overview
--Current Treatment in Newly Diagnosed and Recurrent Glioblastoma
--Adaptive Platform Trials in Glioblastoma
--Advances in Immunotherapy for Glioblastoma
--Additional Targets of Small Molecule Inhibitors in Glioblastoma
--Audience Question and Answer Session and Closing Remarks
Date / Time
Andrew B. Lassman, MD
Associate Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Timothy Cloughesy, MD
Professor and Director
Department of Neurology, Neuro-Oncology Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California
Rimas V. Lukas, MD
Associate Professor of Neurology (Neuro-oncology)
Feinberg School of Medicine
Join us for this live, CME-certified, interactive webinar with neuro-oncology experts Dr. Andrew Lassman, Dr. Tim Cloughesy, and Dr. Rimas Lukas, focused on the latest management approaches for patients with glioblastoma.
The goal of this program is to improve the knowledge, confidence, and competence of learners to apply recent findings and integrate new and emerging agents into the treatment of patients with GBM.
This program is intended for medical oncologists, neuro-oncologists, and other healthcare professionals who care for patients with GBM.
Upon completion of this activity, participants should be able to:
- Integrate new targeted therapeutic agents into clinical practice for patients with glioblastoma multiforme (GBM) based on individual patient and tumor characteristics
- Identify which biomarkers should be assessed in patients with newly diagnosed and recurrent GBM
- Describe the rationale for targeting NTRK gene fusion in GBM and the effects of NTRK fusions on standard treatment selection
- Discuss the current and emerging clinical data on promising small-molecule TKIs and other therapies for specific targets in the treatment of recurrent GBM
- Select optimal treatment for patients with recurrent GBM based on current evidence and molecular markers
- Refer appropriate patients with GBM for enrollment on a clinical trial
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.